Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share - Reconciliation of Net Loss (Details)

v3.21.2
Net Loss Per Share - Reconciliation of Net Loss (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net Loss Per Share        
Net loss $ (7,548,225) $ (8,916,433) $ (21,791,941) $ (19,826,671)
Net loss: Non-controlling interest (115,505) (64,824) (283,846) (228,526)
Net loss attributable to Heat Biologics, Inc. $ (7,432,720) $ (8,851,609) $ (21,508,095) $ (19,598,145)
Weighted-average common shares outstanding, basic (in shares) 25,137,628 20,532,696 24,828,438 13,783,039
Weighted-average common shares outstanding, diluted (in shares) 25,137,628 20,532,696 24,828,438 13,783,039
Net loss per share, basic (in dollars per share) $ (0.30) $ (0.43) $ (0.87) $ (1.42)
Net loss per share, diluted (in dollars per share) $ (0.30) $ (0.43) $ (0.87) $ (1.42)